# EDGAR Filing Document

**Accession Number:** 0001339970
**File Stem:** 0000950170-23-010616
**Filing Date:** 2023-3
**Character Count:** 3970
**Document Hash:** 42dfca93b6fe0c32191f9bec1829d1b1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-23-010616.hdr.sgml**: 20230329

**ACCESSION NUMBER**: 0000950170-23-010616

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20230329

**DATE AS OF CHANGE**: 20230329

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** aTYR PHARMA INC
- **CENTRAL INDEX KEY:** 0001339970
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 203435077
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37378
- **FILM NUMBER:** 23775410

**BUSINESS ADDRESS:**
- **STREET 1:** 10240 SORRENTO VALLEY ROAD
- **STREET 2:** SUITE 300
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** 8587318389

**MAIL ADDRESS:**
- **STREET 1:** 10240 SORRENTO VALLEY ROAD
- **STREET 2:** SUITE 300
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

------

**SCHEDULE 14A INFORMATION**

**Proxy Statement Pursuant to Section 14(a) of the**

**Securities Exchange Act of 1934**

**(Amendment No.)**

------

Filed by the Registrant  Filed by a party other than the Registrant 

Check the appropriate box:

 Preliminary Proxy Statement

 **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**

 Definitive Proxy Statement

 Definitive Additional Materials

 Soliciting Material under § 240.14a-12

**ATYR PHARMA, INC.**

**(Name of Registrant as Specified In Its Charter)**

**(Name of Person(s) Filing Proxy Statement, if other than the Registrant)**

Payment of Filing Fee (Check all boxes that apply):

 No fee required

 Fee paid previously with preliminary materials

 Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

------

![img242908004_0.jpg](img242908004_0.jpg)

INTERNETwww.investorelections.com/LIFE TELEPHONE(866) 648-8133\* E-MAILpaper@investorelections.com When requesting via the Internet or telephone you will need the 12 digit control number located in the shaded box above. aTyr Pharma, Inc. Annual Meeting of Stockholders Meeting Type: Date: Time: Place: Wednesday, May 17, 2023 9:00 AM, Pacific Time Offices of aTyr Pharma, Inc. 10240 Sorrento Valley Road, Suite #300, San Diego, CA 92121 \* If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located above) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material. SEE REVERSE FOR FULL AGENDA

------

![img242908004_1.jpg](img242908004_1.jpg)

aTyr Pharma, Inc. Annual Meeting of Stockholders THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR ON PROPOSALS 1, 2, 3, 4, 5 AND 6 PROPOSAL 1. To elect two Class II directors, as nominated by the Company's Board of Directors, to hold office until the 2026 annual meeting of stockholders or until their successors are duly elected and qualified; 1.01 Timothy P. Coughlin 1.02 Jane A. Gross, Ph.D. 2. To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023; 3. To approve, on an advisory basis, the compensation of the Company's named executive officers; 4. To approve an amendment to the aTyr Pharma, Inc. 2015 Stock Option and Incentive Plan, as amended; 5. To approve an amendment to the Company's Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 85,000,000 to 170,000,000 shares; 6. To approve the authorization to adjourn the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposals 4 or 5; and 7. The transaction of such other business as may properly come before the meeting. <br>

------